Can these February FTSE 250 high-flyers keep on soaring in March?

February has been a great month for the FTSE 250 (INDEXFTSE:MCX), and March is already looking good for further gains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 250 index gained 3.4% in February, beating the 2.3% gain of the FTSE 100. But will that outperformance continue into March? Here are two shares that could keep on going.

Plastic fantastic

Shares in Essentra (LSE: ESNT) soared by 33% in February, for the biggest gain in the FTSE 250 — and at 535p as I write, they’ve put on another couple of pennies since the start of March.

Essentra isn’t a flash new growth star that’s excited the punters, it’s a supplier of specialist plastic, fibre, foam and packaging products that’s turning itself around from a poor 2016. The firm reported a 9% fall in like-for-like revenue, with adjusted EPS falling by 31% to 36.3p and net debt rising slightly to £379m.

But the dividend was maintained, which cheered those shareholders who had been fearing a cut. The disposal of the firm’s Porous Technologies business should complete in the current quarter to significantly reduce debt, and Essentra told us its turnaround plan is “already initiated, focusing on re-establishing stability and accountability“.

There’s a new chief executive, Paul Forman, at the helm now, and I like to see that in a company needing serious remedial work — a new boss can potentially sweep cleaner than an incumbent without being blamed for the past. In fact, Mr Forman described Essentra’s 2016 problems as being “predominantly self-inflicted, and therefore capable of reversal“.

The recovery won’t be immediate, and Mr Forman anticipates a further fall in revenue and operating profit in 2017. But analysts already have a 14% EPS recovery pencilled-in for 2018, putting the shares on a forward P/E of just under 18.

With those retained dividends (yielding around 4%) lending support and debt set to fall, I think February’s gains could presage a strong recovery for Essentra over the next few years.

Hot metal

Results for 2016 gave Bodycote (LSE: BOY) a boost on 28 February, helping send the shares up 19% over the month — and with a small extra gain since, they’re up 38% in three months to 817p.

Results from the metallurgical services specialist showed headline pre-tax profit (excluding exceptionals) falling by 2.2% to £97m, with headline EPS dropping 6.3% to 37p, and net cash plunging from £12.3m to just £1.1m. So why was the market so enthused?

For one thing, the dividend was lifted by 4.6% to 15.8p — that’s only a yield of around 2%, but it’s more than adequately covered at around 2.3 times, and it lends support to analysts who are forecasting further rises this year and next.

Another factor that seems to be playing its part is the cyclical nature of the engineering sector in which Bodycote provides its services. A strong ‘Buy’ consensus for Bodycote from analysts, combined with improving sentiment towards our major aerospace and defence companies, suggests we’re getting past the bottom of the cycle and could be in for a new bull phase.

Chief executive Stephen Harris said: “While our business, by its nature, has limited forward visibility, we continue to demonstrate that we are capable of adapting with great agility to changes in market conditions,” adding that he believes the company will “will generate good returns through the cycle“.

I confess I’m a little nervous about Bodycote’s forward P/E going into 2017 of over 20 with dividends only expected to yield around 2.5%. But if the turnaround is here and Bodycote’s agility is as great as Mr Harris suggests, the shares could be good value.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended Essentra. The Motley Fool UK has recommended Bodycote. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »

Investing Articles

3 top Vanguard ETFs to consider for an ISA or SIPP in 2026

Edward Sheldon believes that these three Vanguard ETFs could be solid investments for a pension (SIPP) or investment account in…

Read more »

Investing Articles

5 growth stocks on Dr James Fox’s watchlist for 2026

Dr James Fox believes these UK and US growth stocks are worth considering as he looks to outperform the stock…

Read more »